1. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML

2. Program

3. Treating Newly Diagnosed AML

4. Case #1: John

5. Case #1: Marrow Results

6. Case #1: Marrow Results (cont)

7. Workup for AML in 2019

8. Diagnostic Workup for AML in 2019

9. Polling Question

10. Phase 3: 7+3 Plus Midostaurin vs Placebo -- CALGB 10603 (RATIFY)

11. Phase 3: 7+3 Plus GO vs 7+3 -- ALFA-0701 Study

12. Phase 3: 7+3 Plus GO vs 7+3 -- ALFA-0701 Study

13. Meta-Analysis of Gemtuzumab Plus 7+3

14. Panel Discussion

15. Case #2: Nancy

16. Case #2: Nancy (cont)

17. Case #2: Nancy (cont)

18. Polling Question

19. Phase 3: GO vs BSC in Older Treatment-Naive AML -- EORTC/GIMEMA AML 19

20. Glasdegib + LDAC Improves Overall Survival

21. Venetoclax + Hypomethylating Agents --- Phase 1b

22. Upfront Therapy of IDH Mutant AML

23. Panel Discussion

24. Case #3: Mary

25. Marrow Results for Mary

26. Polling Question

27. Outcomes of 7+3 in Secondary AML

28. Liposomal Cytarabine/Daunorubicin (CPX-351) vs 7+3 in Older, Newly Diagnosed, High-Risk AML Patients

29. Liposomal Cytarabine/Daunorubicin (CPX-351) vs 7+3 in Older, Newly-Diagnosed, High-Risk AML Patients

30. CPX-351 vs 7+3 in Older, Newly-Diagnosed, High-Risk AML: Landmark Analysis After Transplant

31. Venetoclax + Azacitidine/Decitabine -- Phase 1b

32. Panel Discussion

33. Question & Answer Session

34. Treating Relapsed/Refractory AML

35. Case #4: Joseph

36. Case #4 (cont)

37. Polling Question

38. Treatment of R/R FLT3–Mutated AML

39. Single-Agent FLT3 Inhibitor for Relapsed AML

40. Panel Discussion

41. Treatment of R/R IDH–Mutated AML

42. Case #5: Susan

43. Polling Question

44. Panel Discussion

45. What Is Ahead for AML?

46. Conclusions

47. Take-Home Messages

48. Audience Q&A

49. Abbreviations

50. Abbreviations (cont)